Skip to main content

Table 6 Basic information of included patients from our hospital diagnosed in 2003–2019 after PSM

From: Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma

Variables

Total

Early-onset GSRCC

Late-onset GSRCC

P value

Total

70

35

35

 

Sex

   

1

Male

40 (57.14%)

20 (57.14%)

20 (57.14%)

 

Female

30 (42.86%)

15 (42.86%)

15 (42.86%)

 

Smoke

   

0.255

Never

54 (77.14%)

29 (82.86%)

25 (71.43%)

 

Yes

16 (22.86%)

6 (17.14%)

10 (28.57%)

 

Primary site

   

0.4

Cardia

3 (4.29%)

1 (2.85%)

2 (5.71%)

 

Fundus

3 (4.29%)

1 (2.85%)

2 (5.71%)

 

Antrum

42 (60%)

19 (54.28%)

23 (65.71%)

 

Body

20 (28.57%)

13 (37.14%)

7 (20%)

 

Overlappping/NOS

2 (2.86%)

1 (2.85%)

1 (2.85%)

 

T stage

   

0.576

T1

8 (11.43%)

4 (11.43%)

4 (11.43%)

 

T2

10 (14.28%)

5 (14.29%)

5 (14.29%)

 

T3

10 (14.28%)

7 (20%)

3 (8.57%)

 

T4

42 (60%)

19 (54.28%)

23 (65.71%)

 

N stage

   

0.63

N0

139 (34.49%)

9 (25.71%)

8 (22.86%)

 

N1

60 (14.89%)

2 (5.71%)

5 (14.29%)

 

N2

19 (27.14%)

9 (25.71%)

10 (28.57%)

 

N3

27 (72.86%)

15 (42.86%)

12 (34.29%)

 

M stage

   

0.045

M0

59 (84.29%)

26 (74.29%)

33 (94.29%)

 

M1

11 (15.71%)

9 (25.71%)

2 (5.71%)

 

Lesion classification

   

0.689

Infiltration type

6 (8.57%)

4 (11.43%)

2 (5.71%)

 

Ulcerative type

52 (74.29%)

25 (71.43%)

27 (77.14%)

 

Protuberant type

12 (17.14%)

6 (17.14%)

6 (17.14%)

 

Lymphatic vessel invasion

   

0.621

No

26 (37.14%)

12 (34.29%)

14 (40%)

 

Yes

44 (62.86%)

23 (65.71%)

21(60%)

 

Tumor size

   

0.203

≤ 2 cm

22 (31.43%)

8 (22.86%)

14 (40%)

 

≤ 5 cm

33 (47.14%)

20 (57.14%)

13 (37.14%)

 

 > 5 cm

15 (21.43%)

7 (20%)

8 (22.86%)

 

Examined LNs

   

0.495

≤ 16

10 (14.29%)

6 (17.14%)

4 (11.43%)

 

 > 16

60 (85.71%)

29 (82.86%)

31 (88.57%)

 

Chemotherapy

   

1

No

38 (54.29%)

19 (54.29%)

19 (54.29%)

 

Yes

32 (45.71%)

16 (45.71%)

16 (45.71%)